NCT04899908View on ClinicalTrials.gov

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2026

Conditions
Brain CancerBrain MetastasesMelanomaLung CancerBreast CancerHER2-positive Breast CancerColorectal CancerGastrointestinal CancerSRSSRTWhole Brain RadiationStereotactic RadiationAGuIXNanoparticleCysticBrain Tumor
Interventions
RADIATION

Stereotactic Radiation

Focused radiation beams to treat tumors

DRUG

AGuIX gadolinium-based nanoparticles

Intravenous injection

OTHER

Placebo

Intravenous infusion

Trial Locations (2)

02115

RECRUITING

Brigham and Women's Hospital, Boston

RECRUITING

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

NH TherAguix SAS
All Listed Sponsors
collaborator

NH TherAguix SAS

OTHER

lead

Dana-Farber Cancer Institute

OTHER